Octreotide: 5 agencies, 2009–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on octreotide than on its own caseload: it refused 2 of 6 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 16.9 years separate the first record, 7 May 2009 at PHARMAC (New Zealand), from the most recent, 28 Apr 2026 at TLV (Sweden).
PHARMAC (New Zealand) changed its position: not recommended on 7 May 2009, recommended by 7 May 2009, after a resubmission.
No assessment is on file from SMC (Scotland), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for octreotide by the agencies that label one in English (AWMSG and PBAC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess octreotide, on 7 May 2009; TLV (Sweden) did not open a file until 28 Apr 2026 — an unusually long tail of 16.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 9 years in total.
3 of the 5 agencies here assessed octreotide more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed octreotide.
The full ledger for octreotide reads 11 recommended, 3 not recommended and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2019 | Non-functional neuroendocrine tumours of midgut or suspected midgut origin | The PBAC recommended the Section 100 (Highly Specialised Drugs Program) Authority Required… | source |
| AWMSG (Wales) | 20 Sep 2018 | Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut s… | recommended (limited) | source |
| HAS (France) | 22 Feb 2017 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| HAS (France) | 7 Sep 2016 | Indication extension | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 7 May 2009 | Acromegaly (presurgery) | PTAC advice: Decline · decision reached | source |
10 further decisions for octreotide, across 4 agencies, are not shown here. They include the most recent record on file, 28 Apr 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- lanreotide — same ATC class H01C — Pituitary and hypothalamic hormones
- pasireotide — same ATC class H01C — Pituitary and hypothalamic hormones
- insulin glargine — also decided by TLV in 2026Q2
- epoetin alfa — also decided by TLV in 2026Q2
- anifrolumab — also decided by TLV in 2026Q2
- golimumab — also decided by TLV in 2026Q2
Coverage: 15 decisions for octreotide from 5 agencies, 2009 to 2026. Data to 7 Sep 2026. ATC class H01C — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.